NWU Institutional Repository

Black ginseng: a novel medicine for treating heart failure

dc.contributor.authorDou, Peiyuan
dc.contributor.authorLiu, Linlin
dc.contributor.authorJin, Mozhu
dc.contributor.authorHuang, Jing
dc.contributor.authorLekhooa, Rose Makhotso
dc.contributor.authorRan, Xiaoku
dc.contributor.authorYan, Xiaohui
dc.contributor.researchID29219396
dc.date.accessioned2025-11-27T12:32:20Z
dc.date.issued2024
dc.descriptionJournal Article, Faculty of Health Sciences, Preclinical Drug Development Platform (PCDDP)-- Potchefstroom Campus
dc.description.abstractIntroduction: Black ginseng (BG) was processed by "steaming and drying" (generally nine times) repeatedly to produce "rare saponins" and secondary ginsenosides. Both ginseng (GS) and red ginseng (RG) were commonly used in treating heart failure (HF), and the latter was confirmed to be more potent, implying the presence of rare ginsenosides that contribute positively to the treatment of heart failure. Previous research indicated that rare ginsenosides are more abundant in BG than in RG. Consequently, this study aims to investigate the effects of BG and its components on HF to elucidate the active substances and their underlying mechanisms in the treatment of HF. Methods: The effects of BG and its fractions (water-eluted fraction (WEF), total saponin fraction (TSF), and alcohol-eluted fraction (AEF)) on rats with isoproterenol (ISO)-induced HF were explored, and steroids belonging to the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-gonadal (HPG) axes were determined quantitatively using the ultra-performance liquid chromatography-triple quadrupole tandem mass spectrometry (UPLC-QqQ-MS/MS) method. In addition, 16S rDNA sequencing was performed on the gut microbiota, followed by GC-MS analysis of short-chain fatty acids (SCFAs), and the biochemical indexes related to energy metabolism and the serum cyclic nucleotide system were also analyzed by ELISA. Results: Based on a thorough evaluation of energy metabolism and the endocrine system, it was observed that the effects of BG components on the hypothalamic-pituitary-thyroid (HPT) and HPA axes were more pronounced. Notably, the treatment efficacy of the low dose of the total saponin fraction (TSFL), water decoction (WD), and high dose of the polysaccharide fraction (PSFH) was superior based on pharmacodynamic indicators such as brain natriuretic peptide (BNP), creatine kinase (CK), and estradiol (E2)/T). Furthermore, the WD and BG components exhibited significant effects on androgens (T and androstenedione (A4)). The TSFL group exerts an anti-inflammatory effect by regulating Lactobacillus/Erysipelotrichales. The WD, PSFH, and TSFL may impact inflammatory cytokines through the gut microbiota (Lactobacillus/Erysipelotrichales) and their metabolites (acetate and butyrate), exerting an anti-inflammatory effect. Discussion: The BG and all its split components demonstrated varying levels of efficacy in alleviating HF, and TSF and PSF exhibited a significant protective effect on HF. The main active components in TSF were revealed to be ginsenosides Rk1, Rk3, 20-(S)-Rg3, and 20-(S)-Rh2 by the H9C2 cell experiment. The decoction of BG and its components exhibited a potent impact on androgen hormones, with an elevation trend. This phenomenon may be attributed to the activation of the eNOS-NO pathway through androgen regulation, thereby contributing to its anti-HF activities. The WD, PSFH, and TSFL may exert anti-inflammatory effects through the intestinal flora (Lactobacillaceae/Erysipelotrichaceae) and its metabolites (acetic acid and butyric acid), which affect the inflammatory factors. The different mechanisms of action of each component of HF also reflect the significance and necessity of the overall role of traditional Chinese medicine (TCM). Our research was the first to report that the E2/T is related to HF and can be used as an indicator to evaluate HF.
dc.description.sponsorshipFunding The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the National Natural Science Foundation of China (grant no. 82073985), the Key research and development project of Liaoning Province (grant no. 2023JH2/10300058), and Liaoning Province unveiled the top scientific and technological projects (grant no. 2023JH1/10400030).
dc.identifier.citationLekhooa, Rose Makhotso. et al. 2024. Black ginseng: a novel medicine for treating heart failure. Frontiers in Pharmacology, (2024), 15:1429214, [doi:10.3389/fphar.2024.1429214]
dc.identifier.uri10.3389/fphar.2024.1429214
dc.identifier.urihttp://hdl.handle.net/10394/44412
dc.language.isoen
dc.publisherFrontiers in Pharmacology
dc.subjectSCFAs
dc.subjectUPLC-QqQ-MS/MS
dc.subjectBlack Ginseng and its Fractions
dc.subjectHeart Failure
dc.subjectSteroids
dc.titleBlack ginseng: a novel medicine for treating heart failure
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lekhooa, Rose Makhotso. et al. 2024.pdf
Size:
5.41 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections